

# Anas Younes

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2395043/publications.pdf>

Version: 2024-02-01

183  
papers

15,345  
citations

22099

59  
h-index

18075

120  
g-index

185  
all docs

185  
docs citations

185  
times ranked

15639  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring. <i>Clinical Cancer Research</i> , 2022, 28, 45-56.	3.2	13
2	The impact of anti-CD20-based therapy on hypogammaglobulinemia in patients with follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2022, , 1-10.	0.6	2
3	Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma. <i>Blood Cancer Journal</i> , 2022, 12, 29.	2.8	1
4	Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era. <i>Blood</i> , 2021, 137, 39-48.	0.6	38
5	Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition. <i>Blood</i> , 2021, 137, 2057-2069.	0.6	17
6	Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation. <i>Translational Oncology</i> , 2021, 14, 100977.	1.7	13
7	OncoTree: A Cancer Classification System for Precision Oncology. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 221-230.	1.0	51
8	Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse. <i>Blood Cancer Journal</i> , 2021, 11, 113.	2.8	35
9	Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e410-e421.	2.2	83
10	Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2257-2265.	0.8	32
11	ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. <i>Cell Reports Medicine</i> , 2021, 2, 100350.	3.3	6
12	Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. <i>Blood Advances</i> , 2020, 4, 4669-4678.	2.5	64
13	Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. <i>Blood Cancer Journal</i> , 2020, 10, 74.	2.8	81
14	Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100235.	0.7	4
15	Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 2931-2938.	0.6	13
16	Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. <i>Cancer Discovery</i> , 2020, 10, 440-459.	7.7	103
17	Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma. <i>European Journal of Cancer</i> , 2020, 126, 78-90.	1.3	21
18	Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. <i>Blood</i> , 2020, 135, 735-742.	0.6	86

#	ARTICLE	IF	CITATIONS
19	R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET. <i>Blood</i> , 2020, 136, 39-40.	0.6	3
20	Targeting CD30 in Patients with Hodgkin Lymphoma. <i>Hematologic Malignancies</i> , 2020, , 381-393.	0.2	0
21	Other New Agents for Hodgkin Lymphoma. <i>Hematologic Malignancies</i> , 2020, , 411-416.	0.2	0
22	Recil 2017 Criteria Demonstrated Similar Prognostic Value and Detected a Comparable Treatment Difference between Obinutuzumab- and Rituximab-Chemotherapy Compared with Cheson 2007 and Lugano 2014 Criteria in Patients with Previously Untreated Advanced-Stage Follicular Lymphoma. <i>Blood</i> , 2020, 136, 25-26.	0.6	1
23	Novel therapeutic agents for relapsed classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 105-112.	1.2	16
24	Paradigms for Precision Medicine in Epichaperome Cancer Therapy. <i>Cancer Cell</i> , 2019, 36, 559-573.e7.	7.7	40
25	Will GALEN become more RELEVANT?. <i>Lancet Haematology</i> ,the, 2019, 6, e391-e392.	2.2	0
26	New drugs for new targets in lymphoma. <i>Hematological Oncology</i> , 2019, 37, 105-109.	0.8	2
27	Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. <i>Blood Cancer Journal</i> , 2019, 9, 50.	2.8	75
28	Emerging epigenetic-modulating therapies in lymphoma. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 494-507.	12.5	80
29	Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma. <i>Haematologica</i> , 2019, 104, e163-e166.	1.7	17
30	Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Nonâ€“Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1285-1295.	0.8	388
31	Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. <i>Blood</i> , 2019, 133, 2121-2129.	0.6	46
32	Follicular lymphoma. <i>Nature Reviews Disease Primers</i> , 2019, 5, 83.	18.1	148
33	ABVD plus rituximab <i>versus</i> ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study. <i>Haematologica</i> , 2019, 104, e65-e67.	1.7	11
34	Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2019, 25, 1718-1726.	3.2	26
35	Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. <i>Lancet Haematology</i> ,the, 2019, 6, e67-e78.	2.2	146
36	Dual Inhibition of MCL1 and BCL2 in Lymphoma Using Tumor Targeted Nanoparticles. <i>Blood</i> , 2019, 134, 305-305.	0.6	1

#	ARTICLE	IF	CITATIONS
37	Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of CNS Relapse Treated in the Rituximab Era. <i>Blood</i> , 2019, 134, 1619-1619.	0.6	9
38	Inhibition of PIM Kinases Targets Synthetic Vulnerabilities and Enhances Antigen Presentation in B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 2858-2858.	0.6	1
39	Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study. <i>Blood</i> , 2019, 134, 4026-4026.	0.6	0
40	Immune Checkpoint Inhibition in Hodgkin Lymphoma. <i>HemaSphere</i> , 2018, 2, e20.	1.2	15
41	A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL. <i>Blood</i> , 2018, 131, 1805-1808.	0.6	49
42	Authors' Reply. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 125-126.	1.2	1
43	Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 331-344.	13.9	564
44	Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin,) Tj ETQq0 0 0 rgBT /Overlock 10 863-870.	0.6	22
45	Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1428-1439.	0.8	551
46	Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 942-950.	0.8	273
47	NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 12034-12039.	3.3	41
48	BET Inhibition-Induced GSK3 <sup>β</sup> Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors. <i>Cell Reports</i> , 2018, 24, 2155-2166.	2.9	31
49	Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. <i>Blood Cancer Journal</i> , 2018, 8, 60.	2.8	25
50	Resource Utilization Early after Chimeric Antigen Receptor (CAR) T Cell Infusion for Hematologic Malignancies. <i>Blood</i> , 2018, 132, 616-616.	0.6	1
51	A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma. <i>British Journal of Haematology</i> , 2017, 178, 434-441.	1.2	86
52	Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. <i>Blood</i> , 2017, 130, 472-477.	0.6	65
53	Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis. <i>Cancer Cell</i> , 2017, 31, 731-733.	7.7	37
54	The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 4119-4126.	3.2	17

#	ARTICLE	IF	CITATIONS
55	The landscape of new drugs in lymphoma. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 335-346.	12.5	56
56	Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 4-23.	1.2	1,267
57	CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial. <i>Haematologica</i> , 2017, 102, 1923-1930.	1.7	98
58	Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma. <i>Blood</i> , 2017, 130, 1375-1377.	0.6	37
59	Clinical applications of genome studies. <i>Hematological Oncology</i> , 2017, 35, 67-69.	0.8	0
60	Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma. <i>Haematologica</i> , 2017, 102, 2104-2112.	1.7	41
61	Clinical Trials in the Genomic Era. <i>Journal of Clinical Oncology</i> , 2017, 35, 1011-1017.	0.8	14
62	A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory B- and T-Cell Lymphomas. <i>Blood</i> , 2017, 130, 821-821.	0.6	15
63	Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma. <i>Oncotarget</i> , 2017, 8, 14017-14028.	0.8	48
64	Active Surveillance for Newly Diagnosed Nodular Lymphocyte-Predominant Hodgkin Lymphoma. <i>Blood</i> , 2017, 130, 654-654.	0.6	3
65	Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 23-26.	1.0	23
66	The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints. <i>Haematologica</i> , 2016, 101, 794-802.	1.7	94
67	Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. <i>Lancet Oncology</i> , The, 2016, 17, 622-631.	5.1	149
68	Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma. <i>Current Treatment Options in Oncology</i> , 2016, 17, 31.	1.3	57
69	Targeting Programmed Death 1/Programmed Death Ligand 1 in Lymphoma: A Game Changer. <i>Journal of Oncology Practice</i> , 2016, 12, 107-108.	2.5	1
70	Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. <i>Blood</i> , 2016, 127, 3004-3014.	0.6	244
71	ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma. <i>Haematologica</i> , 2016, 101, 968-975.	1.7	52
72	Promising Novel Agents for Aggressive B-Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 1229-1237.	0.9	9

#	ARTICLE	IF	CITATIONS
73	Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood, 2016, 128, 1458-1464.	0.6	61
74	Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncology, The, 2016, 17, 1283-1294.	5.1	818
75	ACR Appropriateness Criteria® Hodgkin Lymphoma—Unfavorable Clinical Stage I and II. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 384-395.	0.6	3
76	Novel agents in the treatment of Hodgkin lymphoma: Biological basis and clinical results. Seminars in Hematology, 2016, 53, 186-189.	1.8	26
77	Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF- $\kappa$ B—Controlled Oxidative Stress Responses. Cancer Research, 2016, 76, 377-389.	0.4	36
78	Novel immunotherapies in lymphoid malignancies. Nature Reviews Clinical Oncology, 2016, 13, 25-40.	12.5	224
79	Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma. Blood, 2016, 128, 1110-1110.	0.6	35
80	Intervention Versus Observation: What Is the Appropriate Endpoint? Assessment of Endpoints in Patients with Advanced Stage Follicular Lymphoma Who Are Initially Observed. Blood, 2016, 128, 1777-1777.	0.6	2
81	Incidence of Infectious Complications Associated with Bendamustine and Anti-CD20 Monoclonal Antibody Combination at Memorial Sloan Kettering Cancer Center (MSKCC). Blood, 2016, 128, 1778-1778.	0.6	3
82	The Final Report of a Phase I/II Study of Panobinostat in Combination with ICE (Ifosfamide, Carboplatin) Tj ETQq0 0 0 rBT /Overlock 10 Blood, 2016, 128, 1833-1833.	0.6	1
83	Chromosome 9p24.1/PD-L1/PD-L2 Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade). Blood, 2016, 128, 2923-2923.	0.6	5
84	Benchmark of Progression Free Survival for Multiple Lines of Therapy in Follicular Lymphoma Treated in the Rituximab Era. Blood, 2016, 128, 2955-2955.	0.6	4
85	A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory T-Cell Lymphomas. Blood, 2016, 128, 2991-2991.	0.6	21
86	Treatment of Hodgkin lymphoma. , 2016, , 83-93.		1
87	Association of MHC-II, PD-L1, and FoxP3 with Disease Status and Outcomes in Patients with Hodgkin Lymphoma. Blood, 2016, 128, 1774-1774.	0.6	0
88	Outcomes of Follicular Lymphoma Patients By Dynamic FLIPI at Diagnosis and Initial Treatment in the Post-Rituximab Era. Blood, 2016, 128, 4119-4119.	0.6	0
89	Dual Inhibition of Histone Deacetylases and Phosphoinositide 3-Kinase Enhances Therapeutic Activity Against B Cell Lymphoma. Blood, 2016, 128, 293-293.	0.6	0
90	MYC-Dependent PI3K and MCL-1 Feedbacks Attenuate BET Inhibitors Activity in Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 294-294.	0.6	0

#	ARTICLE	IF	CITATIONS
91	XII. Therapeutic exploitation of autologous Tâ€cell activation in Bâ€cell lymphoma. Hematological Oncology, 2015, 33, 67-69.	0.8	0
92	Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood, 2015, 125, 1236-1243.	0.6	199
93	Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. British Journal of Haematology, 2015, 171, 463-470.	1.2	81
94	Emerging drugs for diffuse large B-cell lymphoma. Expert Review of Anticancer Therapy, 2015, 15, 439-451.	1.1	13
95	FDG PET/CT imaging as a biomarker in lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 623-633.	3.3	68
96	Lymphomagenesis in Hodgkin lymphoma. Seminars in Cancer Biology, 2015, 34, 14-21.	4.3	29
97	Novel Targeted Therapies in Diffuse Large B-Cell Lymphoma. Seminars in Hematology, 2015, 52, 126-137.	1.8	24
98	A phase 1 doseâ€escalation study of XmAb<sup>Â®</sup>2513 in patients with relapsed or refractory Hodgkin lymphoma. British Journal of Haematology, 2015, 168, 902-904.	1.2	11
99	Lymphomas and microenvironment: Impact on lymphomagenesis. Seminars in Cancer Biology, 2015, 34, 1-2.	4.3	3
100	Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin: Seeing the Forest and the Trees. Journal of Clinical Oncology, 2015, 33, 2835-2836.	0.8	25
101	BET Inhibitor CPI-0610 Is Well Tolerated and Induces Responses in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma: Preliminary Analysis of an Ongoing Phase 1 Study. Blood, 2015, 126, 1491-1491.	0.6	52
102	An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL) and Follicular Lymphoma (FL). Blood, 2015, 126, 1493-1493.	0.6	5
103	Phase 1 Trial Testing Single Agent CUDC-907, a Novel, Oral Dual Inhibitor of Histone Deacetylase (HDAC) and PI3K: Initial Assessment of Patients with Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL), Including Double Expressor (DE) Lymphoma. Blood, 2015, 126, 257-257.	0.6	3
104	Five-Year Survival Data Demonstrating Durable Responses from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood, 2015, 126, 2736-2736.	0.6	8
105	Phase 1 Study of CB-839, a First-in-Class, Glutaminase Inhibitor in Patients with Multiple Myeloma and Lymphoma. Blood, 2015, 126, 3059-3059.	0.6	17
106	Precision medicine in diffuse large B-cell lymphoma: hitting the target. Haematologica, 2015, 100, 989-93.	1.7	19
107	Targeting CD30 in Patients with Hodgkin Lymphoma. Hematologic Malignancies, 2015, , 343-354.	0.2	0
108	Defining the Incidence and Clinical Impact of Genomic Alterations Across Different Histologic Types of Lymphoma Using a Clinically Validated Comprehensive Targeted Sequencing Assay. Blood, 2015, 126, 2668-2668.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Veliparib (ABT-888), Bendamustine, and Rituximab (VBR) Is Well Tolerated and Efficacious in Patients with Lymphoma: Final Analysis of a Phase 1b Clinical Trial of VB and a Cohort Expansion of Vbr in Patients with B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 2691-2691.	0.6	0
110	Distinctive Genomic Alterations in Testicular Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2015, 126, 3655-3655.	0.6	1
111	Role of CD30 Targeting in Malignant Lymphoma. <i>Current Treatment Options in Oncology</i> , 2014, 15, 210-225.	1.3	19
112	The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2014, 165, 112-116.	1.2	50
113	Brentuximab Vedotin for the Treatment of Patients with Hodgkin Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 27-32.	0.9	15
114	Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naïve patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. <i>Lancet Oncology</i> , The, 2014, 15, 1019-1026.	5.1	246
115	Precision therapy for lymphoma—current state and future directions. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 585-596.	12.5	69
116	From empiric to mechanism-based therapy for peripheral T cell lymphoma. <i>International Journal of Hematology</i> , 2014, 99, 249-262.	0.7	16
117	Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. <i>Annals of Hematology</i> , 2014, 93, 1263-1277.	0.8	48
118	Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. <i>Leukemia and Lymphoma</i> , 2014, 55, 2328-2334.	0.6	48
119	An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma or Follicular Lymphoma. <i>Blood</i> , 2014, 124, 1718-1718.	0.6	10
120	Diffuse large B-cell lymphoma: changing treatment paradigms. <i>Oncology</i> , 2014, 28, 339-41.	0.4	2
121	Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. <i>Lancet Oncology</i> , The, 2013, 14, 1348-1356.	5.1	251
122	MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2013, 162, 336-347.	1.2	39
123	Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. <i>Leukemia and Lymphoma</i> , 2013, 54, 2531-2533.	0.6	120
124	Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2013, 163, 123-126.	1.2	67
125	Brentuximab vedotin: the science of common sense. <i>Leukemia and Lymphoma</i> , 2013, 54, 2089-2090.	0.6	1
126	XIV. The rationale for combining targeted and biological anti-lymphoma drugs. <i>Hematological Oncology</i> , 2013, 31, 81-83.	0.8	7



#	ARTICLE	IF	CITATIONS
127	Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma. <i>Clinical Cancer Research</i> , 2013, 19, 6882-6890.	3.2	103
128	Non-Hodgkin Lymphomas: Advanced Diagnostics & Personalized Therapies. , 2013, , .		2
129	Profiling Genomic Alterations Of Diffuse Large B-Cell Lymphoma (DLBCL) At Diagnosis, Relapse, and Transformation, Using a Novel Clinical Diagnostic Targeted Sequencing Platform. <i>Blood</i> , 2013, 122, 1761-1761.	0.6	3
130	FDG-PET Adapted Sequential Therapy With Brentuximab Vedotin and Augmented ICE Followed By Autologous Stem Cell Transplant For Relapsed and Refractory Hodgkin Lymphoma. <i>Blood</i> , 2013, 122, 2099-2099.	0.6	11
131	A First-In-Man Phase 1 Study Of CUDC-907, a First-In-Class Chemically-Designed Dual Inhibitor Of PI3K and HDAC in Patients With Refractory Or Relapsed Lymphoma and Multiple Myeloma. <i>Blood</i> , 2013, 122, 4363-4363.	0.6	5
132	A Phase I Study Of An Anti-CD30 x Anti-CD16A Bispecific Tandem Antibody, AFM13, In Patients With Relapsed Or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2013, 122, 5116-5116.	0.6	2
133	Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase- $\beta$ , in patients with relapsed/refractory lymphoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8518-8518.	0.8	18
134	A phase II study of single agent mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in patients with diffuse large cell B-cell (DLBCL) and follicular (FL) lymphomas.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8535-8535.	0.8	4
135	Antibody-Drug Conjugates in Hematologic Malignancies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , e108-e113.	1.8	3
136	Brentuximab Vedotin in Transplant-Naïve Patients with Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies. <i>Oncologist</i> , 2012, 17, 1073-1080.	1.9	42
137	Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2197-2203.	0.8	251
138	Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 2183-2189.	0.8	1,332
139	Brentuximab vedotin in systemic T-cell lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 623-632.	1.4	20
140	Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 2776-2782.	0.8	162
141	From drug discovery to biomarker-driven clinical trials in lymphoma. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 643-653.	12.5	25
142	Brentuximab vedotin. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 19-20.	21.5	151
143	Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. <i>Blood</i> , 2012, 119, 4123-4128.	0.6	70
144	The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. <i>Blood</i> , 2012, 119, 4017-4025.	0.6	79

#	ARTICLE	IF	CITATIONS
145	Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma. <i>Blood</i> , 2012, 120, 798-798.	0.6	9
146	Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4. <i>Clinical Cancer Research</i> , 2011, 17, 7058-7066.	3.2	72
147	Optimising the lymphoma response criteria in the era of targeted therapy. <i>Lancet Oncology</i> , The, 2011, 12, 616-617.	5.1	10
148	Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2011, 12, 1222-1228.	5.1	168
149	Brentuximab Vedotin (SGN-35). <i>Clinical Cancer Research</i> , 2011, 17, 6428-6436.	3.2	333
150	CD30-targeted antibody therapy. <i>Current Opinion in Oncology</i> , 2011, 23, 587-593.	1.1	61
151	HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma. <i>Blood</i> , 2011, 117, 2910-2917.	0.6	99
152	The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. <i>Experimental Hematology</i> , 2011, 39, 1007-1017.e1.	0.2	43
153	Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 823-829.	1.9	98
154	Beyond chemotherapy: new agents for targeted treatment of lymphoma. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 85-96.	12.5	73
155	The class I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism. <i>British Journal of Haematology</i> , 2010, 151, 387-396.	1.2	51
156	Temsirolimus Has Activity in Non-Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium. <i>Journal of Clinical Oncology</i> , 2010, 28, 4740-4746.	0.8	181
157	Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas. <i>New England Journal of Medicine</i> , 2010, 363, 1812-1821.	13.9	1,266
158	Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP. <i>Blood</i> , 2010, 116, 2812-2812.	0.6	24
159	A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. <i>British Journal of Haematology</i> , 2009, 146, 171-179.	1.2	230
160	Clinical Development of MGCD0103, An Isotype-Selective HDAC Inhibitor: Pericarditis/Pericardial Effusion in the Context of Overall Safety and Efficacy. <i>Blood</i> , 2009, 114, 4756-4756.	0.6	7
161	A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. <i>Blood</i> , 2008, 111, 1848-1854.	0.6	189
162	Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. <i>Blood</i> , 2008, 112, 1424-1433.	0.6	152

#	ARTICLE	IF	CITATIONS
163	Prognostic significance of serum B-lymphocyte stimulator level in Hodgkin's lymphoma. <i>Haematologica</i> , 2007, 92, 269-270.	1.7	16
164	From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 131-140.	1.1	50
165	Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2005, 132, 051220022257008.	1.2	87
166	A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. <i>Cancer</i> , 2003, 98, 310-314.	2.0	160
167	Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2003, 21, 3526-3534.	0.8	104
168	MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. <i>Blood</i> , 2003, 102, 1019-1027.	0.6	190
169	Radiotherapy Alone for Lymphocyte-Predominant Hodgkin's Disease. <i>Cancer Journal (Sudbury, Mass )</i> , 2002, 8, 377-383.	1.0	64
170	European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. <i>Cancer</i> , 2002, 94, 1731-1738.	2.0	67
171	Functional expression of receptor activator of nuclear factor $\kappa$ B in Hodgkin disease cell lines. <i>Blood</i> , 2001, 98, 2784-2790.	0.6	117
172	Antibiotic Treatment of Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue: An Uncontrolled Trial. <i>Annals of Internal Medicine</i> , 1999, 131, 88.	2.0	206
173	Reed-Sternberg Cells and the TNF Family of Receptors/Ligands. <i>Leukemia and Lymphoma</i> , 1997, 27, 195-204.	0.6	23
174	Phase I Study of Fludarabine and Paclitaxel for the Treatment of Low-Grade Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 1997, 26, 77-82.	0.6	12
175	Soluble CD95 in the Serum of Patients with Low and Intermediate Grade Malignant Lymphomas: Absence of Prognostic Correlations. <i>Leukemia and Lymphoma</i> , 1997, 27, 517-521.	0.6	11
176	In vitro and in vivo biologic effects of Interleukin-3 (IL-3) in follicular Low-Grade lymphoma. <i>Leukemia and Lymphoma</i> , 1997, 26, 17-25.	0.6	2
177	Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. <i>British Journal of Haematology</i> , 1997, 99, 618-624.	1.2	120
178	Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. <i>British Journal of Haematology</i> , 1997, 96, 328-332.	1.2	34
179	CD30 ligand is expressed on resting normal and malignant human B lymphocytes. <i>British Journal of Haematology</i> , 1996, 93, 569-571.	1.2	66
180	Risk Classification for Large Cell Lymphoma using Lactate Dehydrogenase, Beta-2 Microglobulin, and Thymidine Kinase. <i>Leukemia and Lymphoma</i> , 1995, 18, 87-92.	0.6	18

#	ARTICLE	IF	CITATIONS
181	Rising Serum Lactate Dehydrogenase Often Caused by Granulocyte-or Granulocyte-Macrophage Colony Stimulating Factor and not Tumor Progression in Patients with Lymphoma or Myeloma. <i>Leukemia and Lymphoma</i> , 1995, 17, 473-477.	0.6	20
182	Polysomy of chromosome 12 in 60 patients with non-hodgkin's lymphoma assessed by fluorescence in situ hybridization: Differences between follicular and diffuse large cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 1994, 9, 161-167.	1.5	22
183	Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma assessment of activity and toxicity. <i>Cancer</i> , 1990, 66, 2470-2475.	2.0	136